Immunic (IMUX) Liabilities and Shareholders Equity (2013 - 2026)

Immunic has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $189.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 824.89% year-over-year to $189.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $315.9 million (up 48.58% YoY) and the FY2025 annual result came in at $24.1 million, down 41.15% from the prior year.
• Liabilities and Shareholders Equity improved to $189.7 million in Q1 2026 per IMUX's latest filing, from $24.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $189.7 million in Q1 2026 and troughed at $20.5 million in Q1 2025.
• A 5-year average of $87.6 million and a median of $86.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity slumped 80.3% in 2025, then soared 824.89% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $127.8 million in 2022, then plunged by 57.5% to $54.3 million in 2023, then declined by 24.74% to $40.9 million in 2024, then tumbled by 41.15% to $24.1 million in 2025, then soared by 688.88% to $189.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $189.7 million, $24.1 million, and $40.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.